SCHEDULE: FMR LLC and Abigail Johnson Report 9.8% Stake in Stoke Therapeutics
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have reported a 9.8% beneficial ownership stake in Stoke Therapeutics Inc. as of December 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 5,600,920 shares of STOKE THERAPEUTICS INC common stock.
- This aggregate amount represents 9.8% of the total outstanding common stock of STOKE THERAPEUTICS INC.
- FMR LLC holds sole voting power over 5,590,109 shares and sole dispositive power over 5,600,920 shares.
- Abigail P. Johnson, as an individual, holds sole dispositive power over 5,600,920 shares, reflecting her beneficial ownership through FMR LLC.
- FMR LLC is classified as a parent holding company (HC), and Abigail P. Johnson is classified as an individual (IN).
- The filing is an Amendment No. 3 to a previous Schedule 13G statement.
- Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC, are identified as entities beneficially owning shares, with Fidelity Management & Research Company LLC owning 5% or greater.
- Abigail P. Johnson, as Director, Chairman, and CEO of FMR LLC, along with other Johnson family members, are considered a controlling group for FMR LLC through their ownership of Series B voting common shares and a voting agreement.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this filing as moderately positive. The disclosure of a significant 9.8% stake by a prominent institutional investor like FMR LLC suggests a degree of confidence in Stoke Therapeutics Inc., which can be a favorable signal to the market.
Positives
- Significant institutional ownership by FMR LLC (Fidelity) at 9.8% can signal confidence in Stoke Therapeutics Inc. from a major financial institution.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
StockSavvy.ai notes that a significant stake by a major asset manager like FMR LLC (Fidelity) in a biotechnology company like Stoke Therapeutics Inc. can be interpreted as a vote of confidence in the company's long-term prospects or its therapeutic pipeline, especially within the competitive biopharmaceutical industry.
Related Party Transactions
- Abigail P. Johnson's beneficial ownership is linked to her role as Director, Chairman, and CEO of FMR LLC, and the Johnson family's controlling interest in FMR LLC through Series B voting common shares and a shareholders' voting agreement.
Stakeholder Impact
- Shareholders may view the significant institutional ownership by FMR LLC as a positive indicator of long-term investment interest and stability.
- The disclosure provides transparency regarding the ownership structure and control dynamics related to FMR LLC and the Johnson family.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its subsidiaries. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC, referenced for Power of Attorney. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC, referenced for Abigail P. Johnson's Power of Attorney. |
| 2025-12-31 | Date of event which requires filing of this statement (beneficial ownership snapshot). |
| 2026-02-04 | Signature date for FMR LLC and Abigail P. Johnson on the Schedule 13G filing. |
Keywords
STOKE THERAPEUTICS INC, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Fidelity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.